Retatrutide
10 MGRetatrutide (R3 / R-3 / LY3437943) — experimental GIP/GLP-1/Glucagon tri-agonist
Studied therapeutic interests:
Choose quantity
Retatrutide (LY3437943), also referenced as R3, R-3, Reta or retratutide in the research literature, is a next-generation experimental peptide tri-agonist designed to simultaneously activate three key metabolic receptors: the GIP receptor (Glucose-dependent Insulinotropic Polypeptide), the GLP-1 receptor (Glucagon-Like Peptide-1), and the glucagon receptor (GCGR). This research peptide — sometimes spelled "retatrutid" or simply R-3 in some protocols — differs from mono-agonists such as semaglutide and bi-agonists such as tirzepatide through its triple mechanism of action, enabling the study of previously uncharacterized inter-receptor synergies in metabolic signaling.
Preclinical studies published in peer-reviewed journals have shown that combined activation of the three receptors by R3 produces significant synergistic effects. In diet-induced obesity (DIO) murine models, Retatrutide (R-3) reduced food intake 30 to 40% more than GIP/GLP-1 bi-agonists alone. Phase II data (Jastreboff et al., 2023) report balanced agonist activity across the three targets, opening new avenues for fundamental research on energy homeostasis.
In vitro, Retatrutide (R3) is used in somatotroph pituitary cell models, 3T3-L1 adipocyte cultures and MIN6 pancreatic beta cells to study cAMP/PKA pathways, glucose-dependent insulin secretion and cellular energy expenditure. Animal models include DIO rodents, ob/ob mice and streptozotocin-induced insulin resistance.
At OSMOSE Research, Retatrutide R-3 is supplied as a lyophilized powder at HPLC purity ≥ 99.2%, with a complete certificate of analysis including mass spectrometry, endotoxin testing and sterility validation. Manufactured in Europe under GMP standards, this research peptide is shipped to France, Belgium and Switzerland in insulated packaging that preserves product stability.
- Preclinical research on multi-receptor GIP/GLP-1/glucagon synergies
- Cellular models of energy homeostasis and metabolic regulation
- Comparative studies with mono- and bi-agonists (semaglutide, tirzepatide)
- Fundamental research on tri-agonist pharmacology
- In vitro studies of adipogenesis and cellular lipolysis
- Murine DIO (diet-induced obesity) model research
- Pancreatic beta-cell culture studies
- Comparative metabolic signaling research
Retatrutide (R3, R-3, LY3437943) was developed by Eli Lilly as a next-generation tri-agonist peptide. Phase I-II clinical trials (Jastreboff et al., NEJM 2023; Rosenstock et al., Lancet 2023) demonstrated unprecedented effects on body weight and metabolic parameters in preclinical and clinical models. In fundamental research, R-3 is used to decipher synergies between the GIP, GLP-1 and glucagon pathways, notably in diet-induced obesity models (DIO), leptin-deficient mice (ob/ob), and to study the role of co-agonism in central metabolic regulation. Affinity, cAMP activation, β-arrestin recruitment and receptor internalization studies use recombinant HEK-293 cells expressing hGIPR, hGLP-1R and hGCGR. The literature also covers tri-agonism pharmacodynamics, expected vs observed dose-response curves and the role of each pathway in adipose tissue lipolysis and hepatic glucose metabolism.
- HPLC purity ≥ 99.2% verified by RP-HPLC
- Molecular mass certified by ESI-MS mass spectrometry
- Endotoxin test < 0.5 EU/mg by LAL method
- Sterility validation
- Batch-specific certificate of analysis available in PDF
Frequently asked questions
Retatrutide — also referenced as R3, R-3 or LY3437943 — is an experimental tri-agonist peptide targeting GIP, GLP-1 and glucagon receptors simultaneously. It is a research peptide used in fundamental studies of multi-receptor metabolic signaling, differentiated from mono-agonists (semaglutide) and bi-agonists (tirzepatide) by its novel triple mechanism of action.
Yes. R3 and R-3 are common research-literature abbreviations for Retatrutide (full name: LY3437943). Depending on laboratory conventions, you may also see spellings such as "Reta," "R-3 peptide," "retratutide," or "retatrutid." All designate the same GIP/GLP-1/glucagon tri-agonist developed by Eli Lilly.
Unlike semaglutide (GLP-1 mono-agonist) or tirzepatide (GIP/GLP-1 bi-agonist), Retatrutide is a tri-agonist also targeting the glucagon receptor (GCGR). This activation of the glucagon pathway theoretically increases energy expenditure and lipid oxidation, while GIP and GLP-1 modulate insulin secretion and satiety.
No. Retatrutide (R-3, LY3437943) is an experimental peptide intended exclusively for in vitro research. It has no marketing authorization (ANSM, EMA, FDA) and cannot be administered to humans outside of registered clinical trials.
The lyophilized peptide must be stored at -20 °C to preserve its molecular stability. Once reconstituted, the solution should be kept at 4 °C and used within 28 days, with stability validated for up to 30 days under our internal conditions. Avoid repeated freeze-thaw cycles.
Yes. Each Retatrutide batch includes a certificate of analysis covering HPLC purity (≥ 99.2%), molecular mass by ESI-MS, endotoxin test (LAL) and sterility validation. Additional tests are available on request (water content, residual solvents).
Common models include HEK-293 cells recombinantly expressing hGIPR/hGLP-1R/hGCGR for pharmacology studies, 3T3-L1 adipocytes for adipogenesis, MIN6 beta-cells for glucose-dependent insulin secretion, and hepatocyte cultures for hepatic glucose metabolism.
At OSMOSE Research, Retatrutide is supplied in 20 mg lyophilized vials, a format adapted to medium-duration research protocols. Larger packaging is available for longitudinal research laboratories (please contact us).
Complete your research
Often ordered together by our researchers
All products on this page are intended exclusively for in vitro scientific research and laboratory use. They are not intended for human or animal consumption, nor for diagnostic or therapeutic use. The buyer assumes full responsibility for compliance with applicable local regulations.